Blueprint Medicines (LTS:0HOJ) Change In Receivables : $-16.8 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Change In Receivables?

Blueprint Medicines's change in receivables for the quarter that ended in Mar. 2025 was $-1.4 Mil. It means Blueprint Medicines's Accounts Receivable increased by $1.4 Mil from Dec. 2024 to Mar. 2025 .

Blueprint Medicines's change in receivables for the fiscal year that ended in Dec. 2024 was $-32.7 Mil. It means Blueprint Medicines's Accounts Receivable increased by $32.7 Mil from Dec. 2023 to Dec. 2024 .

Blueprint Medicines's Accounts Receivable for the quarter that ended in Mar. 2025 was $78.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Blueprint Medicines's Days Sales Outstanding for the three months ended in Mar. 2025 was 47.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Blueprint Medicines's liquidation value for the three months ended in Mar. 2025 was $-212.2 Mil.

Blueprint Medicines Change In Receivables Historical Data

The historical data trend for Blueprint Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Change In Receivables Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1.85

-11.81

-2.23

-7.65

-32.70

Blueprint Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-17.34	-25.07	19.89	-10.18	-1.40

Blueprint Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.8 Mil.

Blueprint Medicines (LTS:0HOJ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Blueprint Medicines's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	78.083	/	149.413	*	91
=	47.69

2. In Ben Graham's calculation of liquidation value, Blueprint Medicines's accounts receivable are only considered to be worth 75% of book value:

Blueprint Medicines's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	576.237	-	853.473	+	0.75 * 78.083	+	0.5 * 12.953
=	-212.2

Blueprint Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines